Mostrar el registro sencillo del ítem

dc.contributor.advisorPadilla Mier, Alonso
dc.contributor.advisorCastellanos Domínguez, Yeny Zulay
dc.contributor.authorRueda Espinel, Santiago
dc.coverage.spatialBucaramanga (Santander, Colombia)spa
dc.date.accessioned2022-06-13T15:46:47Z
dc.date.available2022-06-13T15:46:47Z
dc.date.issued2022
dc.identifier.urihttp://hdl.handle.net/20.500.12749/16708
dc.description.abstractAntecedentes: el aborto es una entidad muy frecuente a nivel mundial, siendo su tratamiento un tema de interés. Con el advenimiento de conductas menos invasivas, el manejo médico farmacológico se convierte en primera línea, sin embargo, no hay un consenso en torno a la dosificación y vía de administración. Objetivo: identificar los factores clínicos asociados al éxito en el manejo intramural del aborto espontáneo con Misoprostol. Justificación: con este proyecto se busca brindar herramientas al clínico para la selección adecuada e individualizada de las pacientes que cursan con un aborto, las cuales se benefician de recibir manejo farmacológico y no quirúrgico, impactando en la calidad de atención, morbimortalidad de la entidad y reducción de costos por intervenciones innecesarias. Metodología: el diseño es un estudio de cohorte prospectiva, con seguimiento durante 1 mes, que permita establecer asociaciones tras realizar análisis univariado, bivariado y sub-análisis según las variables de confusión. Resultados: 157 participantes cumplen los criterios de inclusión. El tratamiento es exitoso en 116 mujeres (74%). Se identifican como factores asociados al éxito la perdida gestacional en primer trimestre (a partir de semana 13 aumenta el riesgo de un manejo fallido RR 3.49, IC 95% 2.21-5.52), la presencia de sangrado vaginal (RR 0.40, IC 95% 0.21-0.75) y el antecedente de algún parto por vía vaginal (RR 0.45, IC 95% 0.24-0.82). Administrar más de 4 dosis de Misoprostol se asocia con fracaso del manejo (RR 3.15, IC 95% 1.53-6.5). Se debe realizar vigilancia de 1 semana. Conclusiones: el manejo médico del aborto con Misoprostol es seguro y efectivo, se estandariza una dosificación para nuestro medio y se identifican las variables que se asocian con mayor o menor éxito que permitan al clínico la selección individualizada de las pacientes.spa
dc.description.tableofcontents1. RESUMEN ...................................................................................................................4 2. ABSTRACT ...................................................................................................................5 3. INTRODUCCIÓN ..........................................................................................................6 4. PLANTEAMIENTO DEL PROBLEMA DE INVESTIGACIÓN ..............................................8 5. JUSTIFICACIÓN ............................................................................................................9 6. MARCO TEÓRICO ......................................................................................................10 6.1. DEFINICIÓN DEL ABORTO ............................................................................................ 10 6.2. EPIDEMIOLOGÍA.......................................................................................................... 11 6.3. FACTORES DE RIESGO ................................................................................................. 12 6.4. MANIFESTACIONES CLÍNICAS ...................................................................................... 12 6.5. MÉTODOS DIAGNÓSTICOS .......................................................................................... 13 6.6. TRATAMIENTO ............................................................................................................ 15 6.6.1. MANEJO MÉDICO ................................................................................................................ 16 6.6.2. MANEJO EXPECTANTE ......................................................................................................... 22 6.6.3. MANEJO QUIRÚRGICO ......................................................................................................... 22 6.7. FACTORES PREDICTORES DE ÉXITO ............................................................................. 24 7. OBJETIVO GENERAL ..................................................................................................27 8. OBJETIVOS ESPECÍFICOS ...........................................................................................27 9. METODOLOGÍA .........................................................................................................27 9.1. TIPO DE ESTUDIO ........................................................................................................ 27 9.2. POBLACIÓN ................................................................................................................. 28 9.2.1. MUESTRA ............................................................................................................................ 28 9.2.2. TAMAÑO DE MUESTRA ........................................................................................................ 28 9.3. CRITERIOS DE SELECCIÓN ............................................................................................ 29 9.3.1. CRITERIOS DE INCLUSIÓN .................................................................................................... 29 9.3.2. CRITERIOS DE EXCLUSIÓN .................................................................................................... 30 9.4. VARIABLES DEL ESTUDIO ............................................................................................ 30 9.5. PROCEDIMIENTOS DEL ESTUDIO ................................................................................. 30 9.6. PLAN DE ANÁLISIS ....................................................................................................... 32 9.7. CONSIDERACIONES ÉTICAS ......................................................................................... 33 10. RESULTADOS.........................................................................................................34 11. DISCUSIÓN ............................................................................................................45 12. CONCLUSIONES .....................................................................................................51 13. REFERENCIAS BIBLIOGRÁFICAS .............................................................................52 14. ANEXOS ................................................................................................................57spa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleFactores asociados al éxito del manejo médico con misoprostol en el aborto espontáneo: Una cohorte prospectivaspa
dc.title.translatedFactors associated with the success of medical management with misoprostol in spontaneous abortion: A prospective cohortspa
dc.degree.nameEspecialista en Ginecología y Obstetriciaspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.programEspecialización en Ginecología y Obstetriciaspa
dc.description.degreelevelEspecializaciónspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.localTesisspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.subject.keywordsGynecologyspa
dc.subject.keywordsObstetricsspa
dc.subject.keywordsMedical sciencesspa
dc.subject.keywordsHealth sciencesspa
dc.subject.keywordsPharmacological managementspa
dc.subject.keywordsMedical treatmentspa
dc.subject.keywordsBirth controlspa
dc.subject.keywordsContraceptionspa
dc.subject.keywordsSpontaneous abortionspa
dc.subject.keywordsMaternal mortalityspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.relation.references1. Peña García MJ. Guía de Práctica Clínica (GPC) para el manejo médico del aborto en el Hospital Local del Norte - E.S.E ISABU. 2018;spa
dc.relation.references2. Blum J, Winikoff B, Gemzell-Danielsson K, Ho PC, Schiavon R, Weeks A. Treatment of incomplete abortion and miscarriage with misoprostol. International Journal of Gynecology and Obstetrics. 2007;99:186–9.spa
dc.relation.references3. Creinin MD, Barnhart K, Zhang J, Gilles JM, Westhoff C, Huang X. Factors Related to Successful Misoprostol Treatment for Early Pregnancy Failure. Obstetrics & Gynecology. 2006;107(4):901–7spa
dc.relation.references4. Prada E, Biddlecom A, Singh S. Aborto inducido en Colombia: nuevas estimaciones y cambios de 1989 a 2008. Perspectivas Internacionales en Salud Sexual y Reproductiva. 2012spa
dc.relation.references5. Organización Mundial de la Salud. Mortalidad materna. 2018;Nota No. 348.spa
dc.relation.references6. Sur SD, Raine-Fenning NJ. The management of miscarriage. Best Practice and Research: Clinical Obstetrics and Gynaecology, Elsevier Ltd. 2009;23(4):479–91spa
dc.relation.references7. Faúndes A, Fiala C, Tang OS, Velasco A. Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy. International Journal of Gynecology and Obstetrics. 2007;99:172–7spa
dc.relation.references8. Bagratee JS, Khullar V, Regan L, Moodley J, Kagoro H. A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. Human Reproduction. 2004;19(2):266–71spa
dc.relation.references9. Odeh M, Tendler R, Kais M, Maximovsky O, Ophir E, Bornstein J. Early pregnancy failure: Factors affecting successful medical treatment. Israel Medical Association Journal. 2010;12(6):325–8.spa
dc.relation.references10. Rasch V. Unsafe abortion and postabortion care an overview. Acta Obstet Gynecol Scand. 2011;90(7):692–700.spa
dc.relation.references11. Departamento Administrativo Nacional de Estadísticas - DANE. Estadísticas vitales. Bogotá. 2012.spa
dc.relation.references12. Moore K, Persaud TVN, Torchia M. Embriología Clínica. 10th ed. Elsevier; 2016. Capítulo 1.spa
dc.relation.references13. Committee on Practice Bulletins—Gynecology. Early Pregnancy Loss. The American College Of Obstetricians and Gynecologists. 2015;number 150spa
dc.relation.references14. Robinson GE. Pregnancy loss. Best Pract Res Clin Obstet Gynaecol. 2014;28(1):169–78.spa
dc.relation.references15. Farquharson RG, Jauniaux E, Exalto N. Updated and revised nomenclature for description of early pregnancy events. Hum Reprod. 2005;20(11):3008–11spa
dc.relation.references16. Everett C. Incidence and outcome of bleeding before the 20th week of pregnancy: prospective study from general practice. BMJ. 1997;315(7099).spa
dc.relation.references17. Barceló F, De Paco C, López-Espín JJ, Silva Y, Abad L, Parrilla JJ. The management of missed miscarriage in an outpatient setting: 800 versus 600 μg of vaginal misoprostol. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2012;52(1):39–43spa
dc.relation.references18. Hasan R, Baird DD, Herring AH, Olshan AF, Jonsson Funk ML, Hartmann KE. Association between first-trimester vaginal bleeding and miscarriage. Obstetrics and Gynecology. 2009;114(4):860–7spa
dc.relation.references19. Shaunik A, Barnhart KT, Chittams J, Gracia CR, Hummel AC, Sammel MD. Risk Factors for Spontaneous Abortion in Early Symptomatic First-Trimester Pregnancies. Obstetrics & Gynecology. 2005;106(5, Part 1):993–9spa
dc.relation.references20. Tong S, Kaur A, Walker SP, Bryant V, Onwude JL, Permezel M. Miscarriage risk for asymptomatic women after a normal first-trimester prenatal visit. 2008;111(3):710–4spa
dc.relation.references21. Doubilet PM, Benson CB. Diagnostic criteria for nonviable pregnancy early in the first trimester. Society of Radiologists in Ultrasound Multispecialty Panel on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy. N Engl J Med. 2013;369:1443–51spa
dc.relation.references22. Memtsa M, Jauniaux E, Gulbis B, Nyrhinen NC, Jurkovic D. Maternal serum markers in predicting successful outcome in expectant management of missed miscarriage. Reproductive BioMedicine Online, Elsevier. 2017;34(1):98–103.spa
dc.relation.references23. Poulose T, Richardson R, Ewings P, Fox R. Probability of early pregnancy loss in women with vaginal bleeding and a singleton live fetus at ultrasound scan. J Obstet Gynaecol. 2006;26(8):782–4spa
dc.relation.references24. Committee on Practice Bulletins—Gynecology and the Society of Family Planning. Medical management of first-trimester abortion. The American College Of Obstetricians and Gynecologists. 2014;89(3):148–161spa
dc.relation.references25. Committee on Practice Bulletins—Gynecology. Second-Trimester Abortion. The American College Of Obstetricians and Gynecologists. 2013;121(6):1394–406.spa
dc.relation.references26. INVIMA. Mifepristona [Internet]. Expediente 20104433. 2016. Available from: http://consultaregistro.invima.gov.co:8082/Consultas/consultas/consreg_encabc um.jspspa
dc.relation.references27. Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion. Contraception. 2006;74(1):26–30.spa
dc.relation.references28. Tang J, Kapp N, Dragoman M, De Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. International Journal of Gynecology and Obstetrics. 2013;121(2):186–9spa
dc.relation.references29. Jp N, Gml G, Hickey M, Jc V, Dou L. Medical treatments for incomplete miscarriage. Cochrane Library. 2013;(3).spa
dc.relation.references30. Gómez-Sánchez P. Manual FLASOG uso Misoprostol en Ginecoobstetricia. 2013.spa
dc.relation.references31. INVIMA. Acta 20, Radicado 7023192. Ministerio de Salud y Protección Social. 2007spa
dc.relation.references32. Corte Constitucional. Sentencia C-355/06 [Internet]. República de Colombia. 2006. Available from: http://www.corteconstitucional.gov.co/relatoria/2006/c-35506.htmspa
dc.relation.references33. INVIMA. Decreto No. 4444. 2005.spa
dc.relation.references34. Colombia Ministerio de la Protección Social. Resolución 4905 [Internet]. 2006. Available from: https://www.minsalud.gov.co/Normatividad_Nuevo/Resolución 4905 de 2006.PDFspa
dc.relation.references35. Blanchard K, Shochet T, Coyaji K, Nguyen Thi NN, Winikoff B. Misoprostol alone for early abortion: An evaluation of seven potential regimens. Contraception. 2005;72(2):91–7.spa
dc.relation.references36. Gemzell-Danielsson K, Bygdeman M, Aronsson A. Studies on uterine contractility following mifepristone and various routes of misoprostol. Contraception. 2006;74(1):31–5.spa
dc.relation.references37. Gemzell-Danielsson, L Marions, A Rodriguez, BW Spur, PYK Wong MB. Comparison Between Oral and Vaginal Administration of Misoprostol on Uterine Contractility. The American College Of Obstetricians and Gynecologists, Elsevier. 1999;93(2):275–80spa
dc.relation.references38. Granstrom G, Granstrom M, Anderson M. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone mifepristone and an exogenous prostaglandin given. Lancet. 1991;338:1233–6spa
dc.relation.references39. Tang OS, Schweer H, Lee SWH, Ho PC. Pharmacokinetics of repeated doses of misoprostol. Human Reproduction. 2009;24(8):1862–9.spa
dc.relation.references40. von Hertzen H, Piaggio G, Huong NTM, Arustamyan K, Cabezas E, Gomez M, et al. Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled equivalence trial. Lancet. 2007;369(9577):1938–46spa
dc.relation.references41. Morris JL, Winikoff B, Dabash R, Weeks A, Faundes A, Gemzell-Danielsson K, et al. FIGO’s updated recommendations for misoprostol used alone in gynecology and obstetrics. International Journal of Gynecology and Obstetrics. 2017;138(3):363–6.spa
dc.relation.references42. Berghella V, Airoldi J, O’Neill A, Einhorn K, Hoffman M. Misoprostol for second trimester pregnancy termination in women with prior caesarean: A systematic review. BJOG: An International Journal of Obstetrics and Gynaecology. 2009;116(9):1151–7.spa
dc.relation.references43. Goyal V. Uterine rupture in second-trimester misoprostol-induced abortion after cesarean delivery: A systematic review. The American College Of Obstetricians and Gynecologists. 2009;113(5):1117–23spa
dc.relation.references44. Chen BA, Reeves MF, Creinin MD, Gilles JM, Barnhart K, Westhoff C, et al. Misoprostol for treatment of early pregnancy failure in women with previous uterine surgery. American Journal of Obstetrics and Gynecology. 2008;198(6):626.e1-626.e5spa
dc.relation.references45. Fiala C, Cameron S, Bombas T, Parachini M, Agostini A, Lertxundi R, et al. Outcome of first trimester medical termination of pregnancy: definitions and management. European Journal of Contraception and Reproductive Health Care. 2018;23(6):451–7.spa
dc.relation.references46. Creinin MD, Chen MJ. Medical abortion reporting of efficacy: the MARE guidelines. Contraception. 2016;94(2):97–103.spa
dc.relation.references47. Chung T, Leung P, Cheung L, Haines C, Chang A. A medical approach to management of spontaneous abortion using misoprostol. Acta obstetricia et gynecologica Scandinavica. 1997;76:248–51.spa
dc.relation.references48. Cheung LP, Haines CJ, Chang AMZ. Spontaneous abortion: a randomized, controlled trial comparing surgical evacuation with conservative management using misoprostol. Fertility and Sterility. 1999;71(6):1054–9spa
dc.relation.references49. Lemmers M, Verschoor MAC, Oude Rengerink K, Naaktgeboren C, Bossuyt PM, Huirne JAF, et al. MisoREST: Surgical versus expectant management in women with an incomplete evacuation of the uterus after misoprostol treatment for miscarriage: A cohort study. European Journal of Obstetrics Gynecology and Reproductive Biology, Elsevier. 2017;211:83–9spa
dc.relation.references50. Asociacion Medica Mundial. Declaración de Helsinki de la AMM - Principios éticos para las investigaciones médicas en seres humanos. 2000;spa
dc.relation.references51. Manzini JL. Declaración De Helsinki: análisis de la 5a reforma en Edimburgo. Acta bioethica. 2000;6(2):321–34spa
dc.relation.references52. Colombia M de SaludR de. Res. 8430 de 1993. Normas científicas, técnicas y administrativas para la investigación en salud. 1993:1–19spa
dc.relation.references53. Ehrnstén L, Altman D, Ljungblad A, Kallner HK. Efficacy of mifepristone and misoprostol for medical treatment of missed miscarriage in clinical practice-a cohort study. Acta Obstet Gynecol Scand. 2020;99:488–93spa
dc.relation.references54. Mizrachi Y, Shoham G, Leong M, Sagiv R, Horowitz E, Raziel A, et al. Misoprostol treatment for early pregnancy loss: an international survey. Reproductive BioMedicine Online. 2021;42(5):997–1005spa
dc.relation.references55. Lemmers M, Verschoor MAC, Kim BV, Hickey M, Vazquez JC, Mol BWJ, et al. Medical treatment for early fetal death (Less than 24 weeks). Cochrane Database of Systematic Reviews. 2019;2019(6).spa
dc.contributor.cvlacCastellanos Domínguez, Yeny Zulay [0000043222]spa
dc.contributor.cvlacPadilla Mier, Alonso [0000093535]spa
dc.contributor.researchgateCastellanos Domínguez, Yeny Zulay [Yeny-Zulay-Castellanos-Dominguez-2201688252]spa
dc.subject.lembGinecologíaspa
dc.subject.lembObstetriciaspa
dc.subject.lembCiencias médicasspa
dc.subject.lembControl natalspa
dc.subject.lembAnticoncepciónspa
dc.subject.lembAborto espontáneospa
dc.subject.lembMortalidad maternaspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.description.abstractenglishBackground: Abortion is a very common entity worldwide, and its treatment is a topic of interest. With the advent of less invasive therapeutic options, pharmacological medical management becomes the first line, however, there is no consensus as to the dose and route of administration. Objective: To identify clinical factors associated with success in the intramural treatment of abortion with misoprostol. Justification: This project seeks to provide tools to the clinician for the appropriate and individualized selection of patients undergoing an abortion, who benefit from receiving pharmacological and non-surgical management, impacting the quality of care, morbidity, and mortality, and the reduction of costs for unnecessary interventions. Methodology: The design is a prospective cohort study, with a follow-up of one month, which allows us to establish associations after performing univariate, bivariate, and subanalysis according to confounding variables. Results: 157 participants met the inclusion criteria. Treatment was successful in 116 women (74%). Factors associated with success were identified as pregnancy loss in the first trimester (after week 13 the risk of treatment failure increases RR 3.49, 95% CI 2.21-5.52), presence of vaginal bleeding (RR 0.40, 95% CI 0.21 -0.75) and history of vaginal delivery (RR 0.45, 95% CI 0.24-0.82). More than 4 doses of misoprostol were associated with medical treatment failure (RR 3.15, 95% CI 1.53-6.5) and follow-up should be maintained for 1 week. Conclusions: The medical management of abortion with Misoprostol is safe and effective, a dose is standardized for our territory and the variables associated with greater or lesser success are identified, allowing the clinician to make an individualized selection of patients.spa
dc.subject.proposalCiencias de la saludspa
dc.subject.proposalMisoprostolspa
dc.subject.proposalManejo farmacológicospa
dc.subject.proposalTratamiento médicospa
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.description.learningmodalityModalidad Presencialspa


Ficheros en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 2.5 Colombia
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 2.5 Colombia